97-19611. General Principles of Software Validation; Draft Guidance; Availability  

  • [Federal Register Volume 62, Number 143 (Friday, July 25, 1997)]
    [Notices]
    [Pages 40099-40100]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 97-19611]
    
    
    -----------------------------------------------------------------------
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    
    Food and Drug Administration
    [Docket No. 97D-0282]
    
    
    General Principles of Software Validation; Draft Guidance; 
    Availability
    
    Agency: Food and Drug Administration, HHS.
    Action: Notice.
    
    -----------------------------------------------------------------------
    
    SUMMARY: The Food and Drug Administration (FDA) is announcing the 
    availability of a draft guidance entitled ``General Principles of 
    Software Validation.'' This guidance is applicable to medical device 
    software and to software used to design, develop, or manufacture 
    medical devices. This guidance discusses how the general provisions of 
    the Quality System Regulation apply to software and the agency's 
    current approach to evaluating a software validation system.
    
    
    [[Page 40100]]
    
    
    DATES: Written comments by October 1, 1997.
    
    ADDRESSES: Submit written requests for single copies of ``General 
    Principles of Software Validation'' to the Division of Small 
    Manufacturers Assistance (HFZ-220), Center for Devices and Radiological 
    Health (CDRH), Food and Drug Administration, 5600 Fishers Lane, 
    Rockville, MD 20857, 301-443-0806 (outside MD 1-800-638-2041). Send two 
    self-addressed adhesive labels to assist that office in processing your 
    requests. Submit written comments on ``General Principles of Software 
    Validation'' to the Dockets Management Branch (HFA-305), Food and Drug 
    Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857. 
    Requests and comments should be identified with the docket number found 
    in brackets in the heading of this document. A copy of ``General 
    Principles of Software Validation'' and received comments are available 
    for public examination in the Dockets Management Branch between 9 a.m. 
    and 4 p.m., Monday through Friday.
    
    FOR FURTHER INFORMATION CONTACT: E. Stewart Crumpler, Center for 
    Devices and Radiological Health (HFZ-343), Food and Drug 
    Administration, 2094 Gaither Rd., Rockville, MD 20850, 301-594-4659.
    
    SUPPLEMENTARY INFORMATION: This guidance outlines general validation 
    principles that FDA considers to be applicable to the validation of 
    medical device software or the validation of software used to design, 
    develop, or manufacture medical devices. This guidance discusses how 
    the general provisions of the Quality System Regulation apply to 
    software and the agency's current approach to evaluating a software 
    validation system. For example, this guidance lists validation elements 
    which are acceptable to FDA for the validation of software, however, it 
    does not list all of the activities and tasks that must in all 
    instances, be used to comply with the law. An alternative approach may 
    be used if such approach satisfies applicable statutory and regulatory 
    requirements.
        This guidance does not recommend any specific life cycle model or 
    any specific validation technique or method, but does recommend that 
    software validation activities be conducted throughout the entire 
    software life cycle. For each software project, the responsible party 
    should determine and justify the level of validation effort to be 
    applied, and the specific combination of validation techniques to be 
    used.
        The guidance in this document is based on generally recognized 
    software validation processes and could therefore be applicable to any 
    software. For FDA purposes, this guidance is applicable to any 
    regulated medical device related software as defined by the Federal 
    Food, Drug, and Cosmetic Act or by current FDA software and regulatory 
    policy. It is not the intent of this document to determine or identify 
    specifically which software is or is not regulated.
        This guidance represents the agency's current thinking on general 
    principles of software validation. It does not create or confer any 
    rights for or on any person and does not operate to bind FDA or the 
    public. An alternative approach may be used if such approach satisfies 
    the requirements of the applicable statute, regulations, or both.
        Interested persons may, on or before October 1, 1997, submit to the 
    Dockets Management Branch (address above) written comments on ``General 
    Principles of Software Validation.'' Two copies of any comments are to 
    be submitted, except that individuals may submit one copy. Comments are 
    to be identified with the docket number found in brackets in the 
    heading of this document. ``General Principles of Software Validation'' 
    and received comments may be seen in the office above between 9 a.m. 
    and 4 p.m., Monday through Friday. Persons with access to the Internet 
    may obtain the new draft guidance via the World Wide Web (WWW) at 
    ``http://www.fda.gov/cdrh/comp/swareval.html''. The new draft guidance 
    may also be obtained by calling the CDRH Facts-On-Demand system at 800-
    899-0381 or 301-827-0111 from a fax machine with a touch-tone telephone 
    attached or built in. At the first voice prompt press 1 to access DSMA 
    Facts, at the second voice prompt press 2, and enter Shelf number 938 
    followed by the pound sign (#). Then follow the remaining voice prompts 
    to complete your request.
    
        Dated: July 15, 1997.
    Elizabeth D. Jacobson,
    Deputy Director for Science, Center for Devices and Radiological 
    Health.
    [FR Doc. 97-19611 Filed 7-24-97; 8:45 am]
    BILLING CODE 4160-01-F
    
    
    

Document Information

Published:
07/25/1997
Department:
Food and Drug Administration
Entry Type:
Notice
Action:
Notice.
Document Number:
97-19611
Dates:
Written comments by October 1, 1997.
Pages:
40099-40100 (2 pages)
Docket Numbers:
Docket No. 97D-0282
PDF File:
97-19611.pdf